Brian Cheng
Stock Analyst at JP Morgan
(2.26)
# 2,812
Out of 5,090 analysts
73
Total ratings
48.28%
Success rate
-3.27%
Average return
Main Sectors:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OPK OPKO Health | Initiates: Neutral | n/a | $1.34 | - | 1 | Nov 20, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $68 → $81 | $89.65 | -9.65% | 6 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Underweight | $12 → $5 | $9.61 | -47.97% | 5 | Nov 7, 2025 | |
| XNCR Xencor | Maintains: Overweight | $20 → $18 | $17.30 | +4.05% | 5 | Nov 6, 2025 | |
| RVMD Revolution Medicines | Maintains: Overweight | $71 → $82 | $79.64 | +2.96% | 1 | Nov 6, 2025 | |
| ZYME Zymeworks | Maintains: Overweight | $20 → $23 | $26.69 | -13.83% | 3 | Oct 16, 2025 | |
| ALLO Allogene Therapeutics | Downgrades: Underweight | n/a | $1.43 | - | 5 | Oct 10, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Underweight | n/a | $1.21 | - | 1 | Oct 10, 2025 | |
| ABSI Absci | Initiates: Overweight | n/a | $3.58 | - | 1 | Oct 2, 2025 | |
| IMVT Immunovant | Maintains: Overweight | $37 → $33 | $22.84 | +44.48% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $47 | $43.30 | +8.55% | 2 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $20 | $20.97 | -4.63% | 7 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $56.88 | +23.07% | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.60 | - | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $22 | $19.76 | +11.34% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $32.88 | - | 1 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.42 | - | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $7.80 | +323.08% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.78 | +237.08% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $125 | $27.78 | +350.05% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.82 | +1,599.44% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.29 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.53 | +1,023.17% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.13 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.33 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $7.13 | +1,092.15% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $7.59 | +176.68% | 1 | Aug 3, 2021 |
OPKO Health
Nov 20, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.34
Upside: -
Protagonist Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $68 → $81
Current: $89.65
Upside: -9.65%
Intellia Therapeutics
Nov 7, 2025
Downgrades: Underweight
Price Target: $12 → $5
Current: $9.61
Upside: -47.97%
Xencor
Nov 6, 2025
Maintains: Overweight
Price Target: $20 → $18
Current: $17.30
Upside: +4.05%
Revolution Medicines
Nov 6, 2025
Maintains: Overweight
Price Target: $71 → $82
Current: $79.64
Upside: +2.96%
Zymeworks
Oct 16, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $26.69
Upside: -13.83%
Allogene Therapeutics
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.43
Upside: -
Pliant Therapeutics
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.21
Upside: -
Absci
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.58
Upside: -
Immunovant
Sep 30, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $22.84
Upside: +44.48%
Sep 26, 2025
Maintains: Overweight
Price Target: $41 → $47
Current: $43.30
Upside: +8.55%
Sep 18, 2025
Maintains: Overweight
Price Target: $16 → $20
Current: $20.97
Upside: -4.63%
Sep 18, 2025
Initiates: Overweight
Price Target: $70
Current: $56.88
Upside: +23.07%
Aug 15, 2025
Upgrades: Neutral
Price Target: n/a
Current: $3.60
Upside: -
Aug 7, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $19.76
Upside: +11.34%
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $32.88
Upside: -
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $2.42
Upside: -
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $7.80
Upside: +323.08%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.78
Upside: +237.08%
Mar 19, 2024
Upgrades: Neutral
Price Target: $125
Current: $27.78
Upside: +350.05%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.82
Upside: +1,599.44%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.29
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.53
Upside: +1,023.17%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.13
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $3.33
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $7.13
Upside: +1,092.15%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $7.59
Upside: +176.68%